The company focuses on developing rapid-acting versions of popular pharmaceuticals by improving drug penetration and speeding up their onset of action. Transcept has received funding from investors such as Hamilton, Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates. The domain name transoral.com is currently available for purchase. Transcept Pharmaceuticals specializes in creating proprietary products that address therapeutic needs in the field of neuroscience.